---
title: Research Tissue Bank
nct_id: NCT00666549
overall_status: COMPLETED
sponsor: Icahn School of Medicine at Mount Sinai
study_type: OBSERVATIONAL
primary_condition: Myelofibrosis
countries: United States, Italy
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00666549.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00666549"
ct_last_update_post_date: 2019-07-05
last_seen_at: "2026-05-12T06:43:32.685Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Research Tissue Bank

**NCT ID:** [NCT00666549](https://clinicaltrials.gov/study/NCT00666549)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 963
- **Lead Sponsor:** Icahn School of Medicine at Mount Sinai
- **Collaborators:** Myeloproliferative Disorders-Research Consortium, National Cancer Institute (NCI)
- **Conditions:** Myelofibrosis, Idiopathic Myelofibrosis, Essential Thrombocythemia, Polycythemia Vera
- **Start Date:** 2007-09
- **Completion Date:** 2017-03-27
- **CT.gov Last Update:** 2019-07-05

## Brief Summary

This study that will allow for the preservation and/or storage of a small portion one or more of the following tissues:

* Peripheral blood
* Bone marrow
* Bone marrow biopsy
* A phlebotomized unit of blood
* Spleen cells
* Toenail clippings

This material will be used for the study of Myeloproliferative Disorders (MPD) by researchers. The goals of this research study are to understand the causes of MPDs, how to diagnose them more easily and how to treat them better. MPD is a disease affecting hematopoietic stem cells. Hematopoietic stem cells are cells that make blood cells. These stem cells grow in the center portion of the bones called bone marrow. Under some conditions, these cells are also found in blood. There are several diseases, which are classified as MPD. These include polycythemia vera (too many red blood cells), essential thrombocythemia (too many platelets), and idiopathic myelofibrosis (abnormal blood cells and fibers build up in the bone marrow). These syndromes carry a high risk of developing leukemia. It is important to continue to learn more about these blood cancers and to learn more about the effectiveness and potential side effects of various treatments.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Patients diagnosed with Philadelphia chromosome negative myeloproliferative disorders (MPD) polycythemia vera (PV), idiopathic myelofibrosis (IM), and essential thrombocythemia (ET) are eligible.
* Newly diagnose MPD patients as well as previously treated for a MPD are eligible.
* Signed informed consent is required from each patient at the time of enrollment.

Exclusion Criteria:

* Patients currently participating in experimental treatment arms of MPD-RC protocols, or other experimental treatment protocols are not eligible during the period they are on study.
```

## Primary Outcomes

- **To collect and store tissue specimens from patients with MPDs including PV, IM, ET. The samples will be used to conduct laboratory investigations to help define mechanisms involved in the pathophysiology and treatment of these disorders.** _(time frame: 3 years)_

## Locations (11)

- Palo Alto Medical Foundation Research Institute, Palo Alto, California, United States
- Weill Cornell University, Washington D.C., District of Columbia, United States
- University of Georgetown, Washington D.C., District of Columbia, United States
- University of Illinois at Chicago, Chicago, Illinois, United States
- Johns Hopkins, Baltimore, Maryland, United States
- Roswell Park, Buffalo, New York, United States
- Mount Sinai Medical Center, New York, New York, United States
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
- University of Utah, Salt Lake City, Utah, United States
- Ospedali Riuniti di Bergamo, Bergamo, IL, Italy
- University of Florence, Florence, IL, Italy

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.palo alto medical foundation research institute|palo alto|california|united states` — added _(2026-05-12)_
- `locations.weill cornell university|washington d.c.|district of columbia|united states` — added _(2026-05-12)_
- `locations.university of georgetown|washington d.c.|district of columbia|united states` — added _(2026-05-12)_
- `locations.university of illinois at chicago|chicago|illinois|united states` — added _(2026-05-12)_
- `locations.johns hopkins|baltimore|maryland|united states` — added _(2026-05-12)_
- `locations.roswell park|buffalo|new york|united states` — added _(2026-05-12)_
- `locations.mount sinai medical center|new york|new york|united states` — added _(2026-05-12)_
- `locations.university of pennsylvania|philadelphia|pennsylvania|united states` — added _(2026-05-12)_
- `locations.university of utah|salt lake city|utah|united states` — added _(2026-05-12)_
- `locations.ospedali riuniti di bergamo|bergamo|il|italy` — added _(2026-05-12)_
- `locations.university of florence|florence|il|italy` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00666549.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00666549*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*